Gary H Cohen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6502213/publications.pdf

Version: 2024-02-01

257450 315739 3,937 48 24 38 citations g-index h-index papers 49 49 49 2754 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Antibodies to Crucial Epitopes on HSV-2 Glycoprotein D as a Guide to Dosing an mRNA Genital Herpes Vaccine. Viruses, 2022, 14, 540.	3.3	6
2	Using Split Luciferase Assay and Anti-Herpes Simplex Virus Glycoprotein Monoclonal Antibodies To Predict a Functional Binding Site between gD and gH/gL. Journal of Virology, $2021, 95, \ldots$	3.4	11
3	Trivalent nucleoside-modified mRNA vaccine yields durable memory B cell protection against genital herpes in preclinical models. Journal of Clinical Investigation, 2021, 131, .	8.2	17
4	Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine. Vaccine, 2020, 38, 7409-7413.	3.8	23
5	Localization of the Interaction Site of Herpes Simplex Virus Glycoprotein D (gD) on the Membrane Fusion Regulator, gH/gL. Journal of Virology, 2020, 94, .	3.4	14
6	An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection. PLoS Pathogens, 2020, 16, e1008795.	4.7	31
7	Characterizing Epitope Binding Regions of Entire Antibody Panels by Combining Experimental and Computational Analysis of Antibody: Antigen Binding Competition. Molecules, 2020, 25, 3659.	3.8	5
8	Point Mutations in Retargeted gD Eliminate the Sensitivity of EGFR/EGFRvIII-Targeted HSV to Key Neutralizing Antibodies. Molecular Therapy - Methods and Clinical Development, 2020, 16, 145-154.	4.1	15
9	Title is missing!. , 2020, 16, e1008795.		O
10	Title is missing!. , 2020, 16, e1008795.		0
11	Title is missing!. , 2020, 16, e1008795.		O
12	Title is missing!. , 2020, 16, e1008795.		0
13	Nanoscale polarization of the entry fusion complex of vaccinia virus drives efficient fusion. Nature Microbiology, 2019, 4, 1636-1644.	13.3	32
14	Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes. Science Immunology, 2019, 4, .	11.9	72
15	Antibody responses to crucial functional epitopes as a novel approach to assess immunogenicity of vaccine adjuvants. Vaccine, 2019, 37, 3770-3778.	3.8	15
16	Surface Plasmon Resonance Reveals Direct Binding of Herpes Simplex Virus Glycoproteins gH/gL to gD and Locates a gH/gL Binding Site on gD. Journal of Virology, 2019, 93, .	3.4	31
17	Dynamic organization of Herpesvirus glycoproteins on the viral envelope revealed by super-resolution microscopy. PLoS Pathogens, 2019, 15, e1008209.	4.7	17
18	Title is missing!. , 2019, 15, e1008209.		0

#	Article	IF	CITATIONS
19	Title is missing!. , 2019, 15, e1008209.		O
20	Title is missing!. , 2019, 15, e1008209.		0
21	Title is missing!. , 2019, 15, e1008209.		0
22	Recent insights into the structural characterization of herpes simplex virus fusion protein, gB. Future Virology, 2018, 13, 5-7.	1.8	0
23	Using Antibodies and Mutants To Localize the Presumptive gH/gL Binding Site on Herpes Simplex Virus gD. Journal of Virology, 2018, 92, .	3.4	13
24	Vaccine-induced antibodies to herpes simplex virus glycoprotein D epitopes involved in virus entry and cell-to-cell spread correlate with protection against genital disease in guinea pigs. PLoS Pathogens, 2018, 14, e1007095.	4.7	26
25	Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir. Journal of Virology, 2017, 91, .	3.4	26
26	The Fusion Loops of the Initial Prefusion Conformation of Herpes Simplex Virus 1 Fusion Protein Point Toward the Membrane. MBio, 2017, 8, .	4.1	34
27	Global sensing of the antigenic structure of herpes simplex virus gD using high-throughput array-based SPR imaging. PLoS Pathogens, 2017, 13, e1006430.	4.7	25
28	Nasal Immunization Confers High Avidity Neutralizing Antibody Response and Immunity to Primary and Recurrent Genital Herpes in Guinea Pigs. Frontiers in Immunology, 2016, 7, 640.	4.8	9
29	Regulation of Herpes Simplex Virus Glycoprotein-Induced Cascade of Events Governing Cell-Cell Fusion. Journal of Virology, 2016, 90, 10535-10544.	3.4	30
30	Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections. Cell, 2016, 167, 684-694.e9.	28.9	141
31	Using a split luciferase assay (SLA) to measure the kinetics of cell–cell fusion mediated by herpes simplex virus glycoproteins. Methods, 2015, 90, 68-75.	3.8	31
32	Patient-Specific Neutralizing Antibody Responses to Herpes Simplex Virus Are Attributed to Epitopes on gD, gB, or Both and Can Be Type Specific. Journal of Virology, 2015, 89, 9213-9231.	3.4	31
33	Functional Fluorescent Protein Insertions in Herpes Simplex Virus gB Report on gB Conformation before and after Execution of Membrane Fusion. PLoS Pathogens, 2014, 10, e1004373.	4.7	40
34	Repertoire of Epitopes Recognized by Serum IgG from Humans Vaccinated with Herpes Simplex Virus 2 Glycoprotein D. Journal of Virology, 2014, 88, 7786-7795.	3.4	31
35	Dissection of the Antibody Response against Herpes Simplex Virus Glycoproteins in Naturally Infected Humans. Journal of Virology, 2014, 88, 12612-12622.	3.4	63
36	Herpes Virus Fusion and Entry: A Story with Many Characters. Viruses, 2012, 4, 800-832.	3.3	282

#	Article	IF	CITATION
37	Antibody-Induced Conformational Changes in Herpes Simplex Virus Glycoprotein gD Reveal New Targets for Virus Neutralization. Journal of Virology, 2012, 86, 1563-1576.	3.4	46
38	Cascade of Events Governing Cell-Cell Fusion Induced by Herpes Simplex Virus Glycoproteins gD, gH/gL, and gB. Journal of Virology, 2010, 84, 12292-12299.	3.4	185
39	Mutational Evidence of Internal Fusion Loops in Herpes Simplex Virus Glycoprotein B. Journal of Virology, 2008, 82, 7249-7249.	3.4	0
40	Mucosal Administration of CpG Oligodeoxynucleotide Elicits Strong CC and CXC Chemokine Responses in the Vagina and Serves as a Potent Th1-Tilting Adjuvant for Recombinant gD2 Protein Vaccination against Genital Herpes. Journal of Virology, 2006, 80, 5283-5291.	3.4	61
41	Crystal Structure of Glycoprotein B from Herpes Simplex Virus 1. Science, 2006, 313, 217-220.	12.6	493
42	Glycoprotein D Receptor-Dependent, Low-pH-Independent Endocytic Entry of Herpes Simplex Virus Type 1. Journal of Virology, 2005, 79, 6655-6663.	3.4	157
43	Herpes Simplex Virus Glycoprotein D Bound to the Human Receptor HveA. Molecular Cell, 2001, 8, 169-179.	9.7	349
44	Herpes Simplex Virus with Highly Reduced gD Levels Can Efficiently Enter and Spread between Human Keratinocytes. Journal of Virology, 2001, 75, 10309-10318.	3.4	52
45	Entry of Alphaherpesviruses Mediated by Poliovirus Receptor-Related Protein 1 and Poliovirus Receptor. Science, 1998, 280, 1618-1620.	12.6	851
46	Monoclonal Antibodies to Distinct Sites on Herpes Simplex Virus (HSV) Glycoprotein D Block HSV Binding to HVEM. Journal of Virology, 1998, 72, 3595-3601.	3.4	134
47	Glycoprotein C of Herpes Simplex Virus Type 1 Prevents Complement-Mediated Cell Lysis and Virus Neutralization. Journal of Infectious Diseases, 1990, 162, 331-337.	4.0	126
48	Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cells. Nature, 1984, 309, 633-635.	27.8	412